NASDAQ$SNGX

Soligenix Inc · Q2 2025 earnings

Q2 2025 earnings ·

Briefing

Soligenix reported Q2 2025, net loss of $8M.

For Q2 2025, Soligenix reported a net loss of $8M. The Form 10-Q discusses segment trends, liquidity, and management outlook for upcoming periods.

  • Net loss $8M.
  • Soligenix highlights operating priorities and capital allocation.
  • Soligenix highlights operating priorities and capital allocation.

Headline financials

Total Revenue

$2.34K

Previous: $2.34K+0.0%
EPS

-$0.82

Previous: -$1.31+37.4%
Capital Expenditures

-$3.31K

No prior period
Free Cash Flow

-$2.71M

Previous: -$1.64M-64.5%
Net Income

-$2.7M

Previous: -$1.64M-64.3%
Operating Income

-$2.76M

Previous: -$1.74M-58.4%
Gross Profit

$0.00

Previous: $22.9K-100.0%

Revenue & EPS history

Soligenix Inc · Revenue · Quarterly

$2.34K

Q2 2025+0%vs Q2 2024

Forward guidance

The filing discusses Soligenix's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed in MD&A.

Tailwinds

  • Soligenix cites execution and demand supporting the near-term outlook.
  • Liquidity and balance-sheet capacity support operations and shareholder returns.

Headwinds

  • GAAP profitability remained under pressure in Q2 2025.
  • Macro, input costs, and FX may pressure margins quarter to quarter.
  • Segment mix and one-time items can affect comparability versus prior periods.
  • Clinical-stage biotech companies face funding and trial execution risk.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2025

Historical avgQ2 2025

+0.8%

Avg return

Earnings day

+3.6%

Avg return

5 days after

+5.4%

Avg return

30 days after

47%

14 / 30 earnings

Positive

+20.0%

Q2 2025

Best reaction

-9.3%

Q2 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-3.7%+19.7%+45.6%
Q3 2025+7.0%+6.3%+25.8%
Q2 2025+20.0%+51.0%+19.2%
Q1 2025+0.5%-3.6%-2.0%
Q3 2024+0.9%+4.6%-6.9%
Q2 2024+0.0%+1.6%+19.1%
Q1 2024-2.4%-12.2%-42.4%
Q3 2023+0.0%-4.8%+40.5%
Q2 2023+2.2%+4.4%+13.3%
Q1 2023+6.4%+0.0%-5.1%
Q3 2022+0.0%-1.5%-22.4%
Q2 2022+2.3%-1.1%-20.7%
Q1 2022-7.0%+2.3%+39.5%
Q3 2021-1.1%-2.2%-17.4%
Q2 2021+1.1%+2.1%+23.4%
Q1 2021+5.6%+16.9%+36.0%
Q3 2020+1.2%+22.4%+35.3%
Q2 2020-1.9%+3.9%-8.2%
Q1 2020+2.6%+11.1%+24.2%
Q3 2019-5.7%-11.3%+17.0%
Q2 2019-0.9%-2.7%-20.4%
Q1 2019+2.8%+2.8%-2.8%
Q3 2018-3.5%-11.4%-14.9%
Q2 2018+5.0%+2.9%+5.0%
Q1 2018+2.5%+3.7%-1.9%
Q3 2017-1.0%+5.9%+0.0%
Q2 2017-9.3%-3.1%-1.8%
Q1 2017-0.4%-3.1%-15.3%
Q3 2016+0.0%+0.0%-22.4%
Q2 2016+0.0%+3.2%+24.2%
Q1 2016

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro